Limited Competition: AIDS Malignancy Consortium (AMC; UM1 Clinical Trial Required)
ID: 356017Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356017

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-24-028.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the Limited Competition: AIDS Malignancy Consortium (AMC), which aims to support clinical research focused on malignancies associated with HIV. This funding opportunity, with a total of $18.1 million available for the first year, seeks to establish a multi-center cooperative research infrastructure that will enhance treatment and prevention strategies for cancers affecting people with HIV. Eligible applicants are limited to current recipients of the AMC supported under RFA-CA-19-056, and the proposed structure must include operations, clinical trial sites, network laboratories, and a statistical center, ensuring equitable access and inclusion of diverse racial and ethnic groups in clinical trials. The application period opens on December 10, 2024, with all submissions required to be completed electronically, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-CA-24-028-Full-Announcement.html
    RFA-CA-24-028.html
    The National Institutes of Health (NIH) invites applications for the Limited Competition: AIDS Malignancy Consortium (AMC), aimed at supporting clinical research on malignancies associated with HIV. This funding opportunity, with a total of $18.1 million available for the first year, seeks to establish a multi-center cooperative research infrastructure designed to improve treatment and prevention strategies for cancers affecting people with HIV (PWH). Key focus areas include developing clinical interventions, studying the biology of HIV malignancies, and collaboration with local and international research networks. Eligible applicants are limited to current recipients of the AMC supported under RFA-CA-19-056, with only one application allowed per institution. The proposed structure must include operations, clinical trial sites, network laboratories, and a statistical center, with significant involvement from diverse scientific working groups. Applications must adhere strictly to provided guidelines, with a focus on equitable access and inclusion of all racial and ethnic groups in clinical trials. The application period opens on December 10, 2024, and all submissions must be completed electronically. This initiative underscores the NIH's commitment to advancing scientific knowledge, enhancing patient care, and fostering collaboration in cancer research among PWH.
    Similar Opportunities
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research initiatives focused on HIV-associated non-communicable diseases (NCDs) at low- and middle-income country (LMIC) institutions through the R21 Clinical Trial Optional grant. This program aims to support locally relevant research that explores the relationship between HIV infection and the development of NCDs, enhance research capacity, and foster collaborative networks among researchers in LMICs and the U.S. The grant provides funding up to $275,000 over a two-year period, with a submission deadline of December 8, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Co-infection and Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Co-infection and Cancer (R01 Clinical Trial Not Allowed)" aimed at enhancing the understanding of infection-related cancers, particularly the roles of co-infection in cancer development. This initiative encourages mechanistic and epidemiologic studies that explore how infections by multiple agents—both pathogenic and non-pathogenic—can influence cancer risk and progression, with a focus on known oncogenic agents, excluding HIV. Given the significant proportion of cancer cases linked to infectious agents, this research is crucial for developing novel prevention and treatment strategies. Interested applicants, including a variety of educational institutions and organizations, particularly those from underrepresented groups, must submit their applications by November 5, 2025, and can find further details and guidelines at the NIH website or contact NIH Grants Information at grantsinfo@nih.gov.
    Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to Address HIV-Related Comorbidities among Highly Affected Populations Experiencing Health Disparities (R01 - Clinical Trial Required)." This initiative aims to support multilevel and multidisciplinary intervention research focused on improving the quality of life and promoting successful aging among individuals living with HIV, particularly those from racial and ethnic minority groups and lower socioeconomic backgrounds. The funding, which ranges from $5-6 million to support approximately 5-6 awards, will provide a maximum budget of $750,000 annually over five years for projects that address social determinants of health and involve community engagement. Interested applicants can find more details and guidelines on the NIH website, with the application process opening on November 11, 2023, and a submission deadline of December 12, 2025. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the Limited Competition: NCI National Clinical Trials Network - Network Group Statistics and Data Management Centers (U10 Clinical Trial Required). This initiative invites applications primarily from current award recipients under RFA-CA-17-057 to sustain Statistics and Data Management Centers (SDMCs) for the NCI National Clinical Trials Network (NCTN), which focuses on advancing cancer treatment through multi-center clinical trials, particularly late-phase trials and biomarker-driven therapies. The funding, totaling approximately $47 million, aims to support five awards over a project period of up to six years, emphasizing the need for substantial Federal scientific involvement and robust statistical analysis plans. Interested applicants must submit their proposals by January 24, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Co-infection and Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R01 Clinical Trial Not Allowed)" aimed at enhancing the understanding of infection-related cancers, particularly the roles of co-infections with multiple pathogens, excluding HIV. This initiative seeks to investigate the mechanisms and epidemiology of cancer linked to various infectious agents, addressing significant gaps in the current understanding of cancer etiology, with a focus on health disparities in underrepresented populations. Eligible applicants include a wide range of entities such as higher education institutions, nonprofits, and foreign organizations, with no budget limit for applications, although strong preliminary data is required. Key deadlines include an earliest submission date of January 5, 2025, and a close date of January 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-082.html.
    Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Institute on Deafness and Other Communication Disorders (NIDCD), has announced a funding opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R21 Clinical Trial Optional)." This grant aims to stimulate innovative research addressing critical issues related to communication disorders—such as hearing, balance, taste, smell, voice, speech, and language—specifically for individuals living with HIV/AIDS. The initiative encourages multidisciplinary collaborations and supports low-risk clinical trials that do not require FDA oversight, with a total funding limit of $275,000 for two-year projects, and no more than $200,000 in any single year. Interested applicants, including various academic institutions and nonprofits, must submit their proposals by January 7, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for the "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" grant, aimed at enhancing research into the relationship between co-infections and cancer. This initiative encourages exploratory studies that investigate how concurrent or sequential infections by multiple pathogens influence carcinogenesis, with a focus on mechanistic and epidemiological insights rather than clinical trials. The grant supports research that may inform cancer prevention and treatment strategies, particularly concerning infection-related cancers, with a maximum award of $275,000 for a two-year project period. Applications are due starting January 16, 2025, and interested applicants can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-083.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for The Confluence of Cancer Stigma and HIV Stigma in HIV-positive Individuals Diagnosed with Cancer (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at researching the intersection of cancer stigma and HIV stigma in individuals diagnosed with both conditions. This initiative seeks to advance understanding of how these stigmas affect cancer outcomes among HIV-positive individuals, promote stigma reduction interventions, and encourage research in areas with high HIV-cancer burdens. The NIH plans to award up to six R01 grants, each with a ceiling of $500,000, as part of a total estimated funding pool of $5 million, with the NOFO expected to be published in late Summer 2024 and applications due in late Fall 2024. Interested applicants are encouraged to prepare by reviewing related presentations and materials available online.